Dyadic announces strategic partnership agreement to develop affordable rabies prophylactics and vaccines using its proprietary c1 cell microbial protein production platform

Jupiter, fla. and bunnik, the netherlands, feb. 28, 2024 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health today announced its dutch subsidiary, dyadic nederland bv has entered into a strategic partnership agreement and collaboration with rabian bv (“rabian”), a dutch innovative sme founded by experienced entrepreneurs and vaccine scientists. the aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing dyadic's c1 protein production platform. this collaboration seeks to address the global burden of rabies, a disease that annually claims tens of thousands of lives.
DYAI Ratings Summary
DYAI Quant Ranking